Literature DB >> 25441688

Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event.

Matthew D Geller1, Ying Pei2, Stephen E Spurgeon3, Connie Durum4, Nicky J Leeborg5.   

Abstract

The t(4;14) (p16; q32) with fusion of the IGH (immunoglobulin heavy chain) and FGFR3 (fibroblast growth factor receptor 3) genes are rarely present in patients with chronic lymphocytic leukemia (CLL), with only two previously reported cases. We herein describe a unique case of CLL with the occurrence of a t(4;14) (p16;q32), trisomy 12, and deletion of 11q13-q23 in the same clonal cells. In contrast to myeloma, in which FGFR3 translocations are a common early cytogenetic hit, FGFR3 rearrangement in CLL appears to occur later in the disease course.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic lymphocytic leukemia; FISH; cytogenetic translocation; prognosis

Mesh:

Substances:

Year:  2014        PMID: 25441688     DOI: 10.1016/j.cancergen.2014.09.004

Source DB:  PubMed          Journal:  Cancer Genet


  3 in total

1.  Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature.

Authors:  Marc DE Braekeleer; Corine Tous; Nadia Guéganic; Marie-Josée LE Bris; Audrey Basinko; Frédéric Morel; Nathalie Douet-Guilbert
Journal:  Mol Clin Oncol       Date:  2016-02-26

2.  Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma.

Authors:  Eva Sipos; Kata Hegyi; Andrea Treszl; Zita Steiber; Gabor Mehes; Nikoletta Dobos; Klara Fodor; Gabor Olah; Lorant Szekvolgyi; Andrew V Schally; Gabor Halmos
Journal:  Oncol Rep       Date:  2017-03-08       Impact factor: 3.906

3.  Coexistence of t(2;14;11)(p16.1;q32;q23) and t(14;19)(q32;q13.3) chromosome translocations in a patient with chronic lymphocytic leukemia: A case report.

Authors:  Guangming Liu; Zhongmei Wen; Xianglan Lu; Young Mi Kim; Xianfu Wang; Rebecca M Crew; Mohamad A Cherry; Shibo Li; Yuanyuan Liu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.